Trial · NCT03230838
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With ≥1 Adverse Events (AEs) | Ceftolozane/Tazobactam | 59 | Participants | ||
| Number of Participants With ≥1 Adverse Events (AEs) | Meropenem | 20 | Participants | ||
| Number of Participants Discontinuing Study Therapy Due to AE | Ceftolozane/Tazobactam | 1 | Participants | ||
| Number of Participants Discontinuing Study Therapy Due to AE | Meropenem | 0 | Participants | ||
| Percentage of Participants With a Clinical Response of Cure at the Test of Cure Visit | Ceftolozane/Tazobactam | 88.7 | 95% Confidence Interval 79.31 to 94.18 | Percentage of participants | |
| Percentage of Participants With a Clinical Response of Cure at the Test of Cure Visit | Meropenem | 95.8 | 95% Confidence Interval 79.76 to 99.26 | Percentage of participants | |
| Percentage of Participants With a Clinical Response of Cure at the End of Treatment Visit | Ceftolozane/Tazobactam | 94.4 | 95% Confidence Interval 86.39 to 97.79 | Percentage of participants | |
| Percentage of Participants With a Clinical Response of Cure at the End of Treatment Visit | Meropenem | 100.0 | 95% Confidence Interval 86.20 to 100.00 | Percentage of participants | |
| Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the Test of Cure Visit | Ceftolozane/Tazobactam | 84.5 | 95% Confidence Interval 74.35 to 91.12 | Percentage of participants | |
| Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the Test of Cure Visit | Meropenem | 87.5 | 95% Confidence Interval 69.00 to 95.66 | Percentage of participants | |
| Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the End of Treatment Visit | Ceftolozane/Tazobactam | 93.0 | 95% Confidence Interval 84.55 to 96.95 | Percentage of participants | |
| Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the End of Treatment Visit | Meropenem | 95.8 | 95% Confidence Interval 79.76 to 99.26 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03230838/results